protein B23 is a silver-staining acidic phosphoprotein found in the preribosomal ribonucleoprotein particles in nucleoli of Novikoff hepatoma cells
Also Known As:
B23 protein, mouse; B23NP protein, rat; NPM1 protein, human; Npm1 protein, mouse; Npm1 protein, rat; nucleolar phosphoprotein B23; nucleolar phosphoprotein B23, human; nucleolar protein B23; nucleolar protein NO38, mouse; nucleophosmid; nucleophosmin 1, mouse; nucleophosmin 1, rat; nucleophosmin protein, human; numatrin; numatrin protein, human; phosphoprotein B23, nucleolus; protein B23
Networked: 524 relevant articles (7 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Falini, Brunangelo: 32 articles (05/2015 - 03/2002)
2. Mecucci, Cristina: 15 articles (05/2008 - 01/2005)
3. Martelli, Maria Paola: 14 articles (05/2015 - 06/2006)
4. Martelli, Massimo F: 13 articles (11/2010 - 01/2005)
5. Falini, B: 12 articles (02/2015 - 02/2000)
6. Liso, Arcangelo: 11 articles (01/2011 - 01/2005)
7. Amin, Hesham M: 10 articles (09/2015 - 09/2003)
8. Medeiros, L Jeffrey: 10 articles (12/2013 - 09/2003)
9. Bolli, Niccolò: 10 articles (01/2011 - 04/2006)
10. Lai, Raymond: 9 articles (04/2013 - 09/2003)

Related Diseases

1. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
2. Neoplasms (Cancer)
3. Residual Neoplasm
4. Dislocations
5. Wilms Tumor (Wilm's Tumor)
11/01/2012 - "Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression."
11/01/2012 - "We compared the clinical value of minimal residual disease (MRD) monitoring by cytofluorimetric methods, Wilms tumor gene 1 (WT1) expression and the study of nucleophosmin gene (NPM) mutations in a series of 26 patients with NPM-mutated de novo acute myeloid leukemia (NPM-AML) who achieved complete hematological remission after conventional chemotherapy. "
06/01/2012 - "Patients were also assessed for the presence of FLT3 (fms-like tyrosine kinase receptor-3), NPM1 (nucleophosmin), CEBPA, WT1 (Wilms tumor 1), IDH1 (isocitrate dehydrogenase 1) and IDH2 mutations. "
10/01/2011 - "We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy. "
08/01/2010 - "The review focuses on research advances abroad in this field including gene mutations suggesting bad prognosis such as FMS-related tyrosine kinase 3 gene mutation, Baalc gene and ETS-related gene hyperexpression, Wilms' tumor gene mutation and other gene mutations as well as gene mutations suggesting good prognosis such as nucleophosmin gene mutation, mixed lineage leukemia-partial tandem duplication, CCAAT/enhancer-binding protein α gene mutation."

Related Drugs and Biologics

1. Formaldehyde (Formol)
2. anaplastic lymphoma kinase
3. Phosphotransferases (Kinase)
4. tyrosine receptor (receptor, tyrosine)
5. fms-Like Tyrosine Kinase 3
6. DNA (Deoxyribonucleic Acid)
7. Small Interfering RNA (siRNA)
8. Protein-Tyrosine Kinases (Tyrosine Kinase)
9. Proteins (Proteins, Gene)
10. Messenger RNA (mRNA)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Transplantation (Transplant Recipients)